Ubs Group Ag Xencor Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Xencor Inc stock. As of the latest transaction made, Ubs Group Ag holds 89,457 shares of XNCR stock, worth $2.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

89,457

Previous 83,195 7.53%

Holding current value

$2.12 Million

Previous $1.57 Million 14.23%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.7 - $21.65 $98,313 - $135,572	6,262 Added 7.53%	89,457 $1.8 Million
Q2 2024 Aug 13, 2024	SELL	$18.21 - $24.5 $2.32 Million - $3.13 Million	-127,610 Reduced 60.53%	83,195 $1.57 Million
Q1 2024 May 13, 2024	BUY	$18.65 - $26.52 $3.89 Million - $5.54 Million	208,805 Added 10440.25%	210,805 $4.67 Million
Q3 2023 Nov 09, 2023	SELL	$20.08 - $25.39 $1.58 Million - $2 Million	-78,915 Reduced 97.53%	2,000 $40,000
Q2 2023 Aug 11, 2023	BUY	$24.77 - $29.9 $721,921 - $871,435	29,145 Added 56.3%	80,915 $2.02 Million
Q1 2023 May 12, 2023	SELL	$25.95 - $36.95 $1.3 Million - $1.86 Million	-50,231 Reduced 49.25%	51,770 $1.44 Million
Q4 2022 Feb 08, 2023	BUY	$24.79 - $30.86 $2 Million - $2.49 Million	80,625 Added 377.18%	102,001 $2.66 Million
Q3 2022 Nov 10, 2022	BUY	$24.62 - $32.44 $14,304 - $18,847	581 Added 2.79%	21,376 $555,000
Q2 2022 Aug 10, 2022	SELL	$19.74 - $29.01 $1.41 Million - $2.07 Million	-71,250 Reduced 77.41%	20,795 $569,000
Q1 2022 May 16, 2022	BUY	$26.68 - $41.63 $411,885 - $642,683	15,438 Added 20.15%	92,045 $2.46 Million
Q4 2021 Feb 14, 2022	BUY	$33.67 - $43.44 $892,490 - $1.15 Million	26,507 Added 52.91%	76,607 $3.07 Million
Q3 2021 Nov 15, 2021	BUY	$30.65 - $35.68 $1.09 Million - $1.26 Million	35,418 Added 241.23%	50,100 $1.64 Million
Q2 2021 Aug 13, 2021	SELL	$34.33 - $44.68 $2.43 Million - $3.16 Million	-70,746 Reduced 82.81%	14,682 $506,000
Q1 2021 May 12, 2021	BUY	$40.81 - $53.88 $1.77 Million - $2.34 Million	43,452 Added 103.52%	85,428 $3.68 Million
Q4 2020 Feb 11, 2021	BUY	$36.63 - $47.63 $769,230 - $1 Million	21,000 Added 100.11%	41,976 $1.83 Million
Q3 2020 Nov 12, 2020	SELL	$30.09 - $43.02 $384,189 - $549,279	-12,768 Reduced 37.84%	20,976 $813,000
Q2 2020 Jul 31, 2020	SELL	$27.76 - $33.42 $1.5 Million - $1.8 Million	-53,907 Reduced 61.5%	33,744 $1.09 Million
Q1 2020 May 01, 2020	SELL	$20.69 - $37.79 $947,519 - $1.73 Million	-45,796 Reduced 34.32%	87,651 $2.62 Million
Q4 2019 Feb 14, 2020	SELL	$32.75 - $41.43 $698,295 - $883,370	-21,322 Reduced 13.78%	133,447 $4.59 Million
Q3 2019 Nov 14, 2019	BUY	$33.73 - $46.27 $3.52 Million - $4.82 Million	104,213 Added 206.13%	154,769 $5.22 Million
Q2 2019 Aug 14, 2019	BUY	$29.6 - $40.93 $1.5 Million - $2.07 Million	50,556 New	50,556 $2.07 Million
Q1 2019 May 14, 2019	SELL	$27.85 - $38.09 $2.39 Million - $3.26 Million	-85,646 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$32.39 - $42.05 $2.75 Million - $3.57 Million	85,005 Added 13261.31%	85,646 $3.1 Million
Q3 2018 Nov 14, 2018	SELL	$35.69 - $47.65 $122,523 - $163,582	-3,433 Reduced 84.27%	641 $25,000
Q2 2018 Aug 14, 2018	SELL	$28.41 - $42.41 $53,922 - $80,494	-1,898 Reduced 31.78%	4,074 $151,000
Q1 2018 May 15, 2018	BUY	$21.18 - $33.78 $103,485 - $165,049	4,886 Added 449.91%	5,972 $179,000
Q4 2017 Feb 14, 2018	SELL	$19.29 - $24.83 $6,481 - $8,342	-336 Reduced 23.63%	1,086 $24,000
Q3 2017 Nov 14, 2017	BUY	$19.61 - $23.35 $5,039 - $6,000	257 Added 22.06%	1,422 $33,000
Q2 2017 Aug 14, 2017	BUY	N/A	694 Added 147.35%	1,165 $25,000
Q1 2017 Nov 14, 2017	BUY	N/A	471	471 $11,000

Others Institutions Holding XNCR

# of Institutions

215

Shares Held

71.5M

Call Options Held

2.5K

Put Options Held

7.9K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.42B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account